Sean Sheridan, Principal, Charles River Associates to Speak at TKG’s BPCIA Patent Dance: Navigating the Biosimilar Litigation Landscape in 2020 LIVE Webcast

Top Quote The Knowledge Group, the leading producer of regulatory focused webcasts, has announced today that Sean Sheridan, Principal, Charles River Associates will speak at its webcast entitled, “BPCIA Patent Dance: Navigating the Biosimilar Litigation Landscape in 2020.” This event is scheduled for February 6, 2020, from 3:00 pm to 4:00 pm (ET). End Quote
  • (1888PressRelease) February 03, 2020 - For further details, please visit:

    About Sean Sheridan
    Dr. Sheridan is a principal in the Intellectual Property Practice at Charles River Associates. He has addressed a broad range of financial and economic issues in the context of litigation, including lost profits, unjust enrichment, reasonable royalty, commercial success, irreparable harm, and the economic prong of the domestic industry requirement in Section 337 ITC matters. The engagements he has worked on span a wide range of industries, and include pharmaceuticals, biologics, diagnostics and medical devices. Previously, Dr. Sheridan was as an assistant director at the technology transfer office at the University of Chicago, where he worked for five years, focusing primarily on the commercialization of early stage technologies. Dr. Sheridan was named to the IAM Patent 1000: The World’s Leading Patent Professionals (economic experts) in 2019.

    About Charles River Associates
    Charles River Associates is a leading global consulting firm that offers economic, financial, and strategy expertise to major law firms, corporations, accounting firms, and governments around the world.

    With proven skills in complex cases and exceptional strength in analytics, CRA consultants have provided astute guidance to clients in thousands of successful engagements. We offer litigation and regulatory support, business strategy and planning, market and demand forecasting, policy analysis, and risk management consulting.

    Our success stems from the outstanding capabilities of our consultants, many of whom are recognized as experts in their respective fields; our close relationships with a select group of respected academic and industry experts; and from a corporate philosophy that stresses interdisciplinary collaboration and responsive service.

    Event Synopsis:
    Since the beginning of 2019, the number of biosimilar litigation - particularly those concerning the Biologics Price Competition and Innovation Act (BPCIA) “patent dance” - has drastically increased. One of the notable BCPIA cases that are being closely watched, is Amgen’s legal battle with Novartis’ Sandoz arm over the Enbrel patent, in which the former intends to hold commercial exclusivity for Enbrel until 2029. The legal precedents established in this dispute are expected to impact the biosimilar market as well as the pending and future biosimilar patent lawsuits.

    With the changing biosimilar landscape and stiffer competition in the backdrop, counsel to drug companies should keep an eye out for these lawsuits and other legal developments to devise effective patent management and litigation strategies.

    Listen to patent experts, Sean Sheridan (Charles River Associates) and Eberle Schultz (O'Melveny & Myers LLP) as they provide the audience with an in-depth analysis of the recent biosimilar litigation trends relating to the BPCIA patent dance. Speakers will also offer the best patent management and litigation practices in light of the recent developments.

    This LIVE Webcast will discuss the following key provisions:

    • The BPCIA Patent Dance – Statistics and Recent Trends
    • Notable Cases and Court Decisions
    • Best Patent Management Practices
    • Effective Litigation Strategies
    • Outlook

    About The Knowledge Group
    The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit:

  • FB Icon Twitter Icon In-Icon
Contact Information